The global human microbiome market is expected to grow at a CAGR of around 16.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing awareness about the importance of gut health and its relation with various diseases such as obesity, diabetes, and cancer. The increasing prevalence of these diseases is also driving the growth of this market.
The gastrointestinal tract human micobiome segment accounted for a major share in 2018 owing to its wide applications in treatment and diagnosis. This segment is expected to maintain its dominance throughout the forecast period due to factors such as high demand for probiotics and prebiotics which are used in treatment and diagnosis procedures.
Some Of The Growth Factors Of This Market:
- The human microbiome is a complex ecosystem of microorganisms that live in and on the human body.
- The human microbiome is composed of trillions of bacteria, viruses, fungi, and other microbes that live in the gut, mouth, skin and elsewhere on the body.
- The human microbiome plays an important role in maintaining health by helping to regulate immune function and metabolism as well as aiding digestion.
- There are many factors that can affect the composition of a person's microbiome including genetics, diet, environment (e.g., living conditions), medication use (e.g., antibiotics), age at which they were weaned from breast milk or formula feeding.
- Factors such as antibiotic use can have a significant impact on the composition of one's microbiota.
Industry Growth Insights published a new data on “Human Micobiome Market”. The research report is titled “Human Micobiome Market research by Types (Gastrointestinal Tract Human Micobiome, Urogenital Tract Human Micobiome, Other), By Applications (Treatment, Diagnosis, ), By Players/Companies Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd, Enterologics, Metabogen, Metabiomics, Ritter Pharmaceuticals, Osel, Symberix, Miomics, Symbiotix Biotherapies, MicroBiome Therapeutics LLC, ”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Micobiome Market Research Report
By Type
Gastrointestinal Tract Human Micobiome, Urogenital Tract Human Micobiome, Other
By Application
Treatment, Diagnosis,
By Companies
Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd, Enterologics, Metabogen, Metabiomics, Ritter Pharmaceuticals, Osel, Symberix, Miomics, Symbiotix Biotherapies, MicroBiome Therapeutics LLC,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Human Micobiome Market Report Segments:
The global Human Micobiome market is segmented on the basis of:
Types
Gastrointestinal Tract Human Micobiome, Urogenital Tract Human Micobiome, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment, Diagnosis,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Vedanta
- Seres Therapeutics
- Second Genome
- Rebiotix
- ActoGeniX
- Enterome BioScience
- AvidBiotics
- 4D Pharma Research Ltd
- Enterologics
- Metabogen
- Metabiomics
- Ritter Pharmaceuticals
- Osel
- Symberix
- Miomics
- Symbiotix Biotherapies
- MicroBiome Therapeutics LLC
Highlights of The Human Micobiome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gastrointestinal Tract Human Micobiome
- Urogenital Tract Human Micobiome
- Other
- By Application:
- Treatment
- Diagnosis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Micobiome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The human microbiome is the collection of all the bacteria, viruses, and other microorganisms that live in and on humans. These microbes play an important role in human health by helping to digest food, regulating our immune system, and contributing to our overall well-being.
Some of the key players operating in the human micobiome market are Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd, Enterologics, Metabogen, Metabiomics, Ritter Pharmaceuticals, Osel, Symberix, Miomics, Symbiotix Biotherapies, MicroBiome Therapeutics LLC.
The human micobiome market is expected to register a CAGR of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Micobiome Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Micobiome Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Micobiome Market - Supply Chain
4.5. Global Human Micobiome Market Forecast
4.5.1. Human Micobiome Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Micobiome Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Micobiome Market Absolute $ Opportunity
5. Global Human Micobiome Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Micobiome Market Size and Volume Forecast by Type
5.3.1. Gastrointestinal Tract Human Micobiome
5.3.2. Urogenital Tract Human Micobiome
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Micobiome Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Micobiome Market Size and Volume Forecast by Application
6.3.1. Treatment
6.3.2. Diagnosis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Micobiome Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Micobiome Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Micobiome Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Micobiome Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Micobiome Demand Share Forecast, 2019-2026
9. North America Human Micobiome Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Micobiome Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Micobiome Market Size and Volume Forecast by Application
9.4.1. Treatment
9.4.2. Diagnosis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Micobiome Market Size and Volume Forecast by Type
9.7.1. Gastrointestinal Tract Human Micobiome
9.7.2. Urogenital Tract Human Micobiome
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Micobiome Demand Share Forecast, 2019-2026
10. Latin America Human Micobiome Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Micobiome Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Micobiome Market Size and Volume Forecast by Application
10.4.1. Treatment
10.4.2. Diagnosis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Micobiome Market Size and Volume Forecast by Type
10.7.1. Gastrointestinal Tract Human Micobiome
10.7.2. Urogenital Tract Human Micobiome
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Micobiome Demand Share Forecast, 2019-2026
11. Europe Human Micobiome Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Micobiome Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Micobiome Market Size and Volume Forecast by Application
11.4.1. Treatment
11.4.2. Diagnosis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Micobiome Market Size and Volume Forecast by Type
11.7.1. Gastrointestinal Tract Human Micobiome
11.7.2. Urogenital Tract Human Micobiome
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Groth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Micobiome Demand Share, 2019-2026
12. Asia Pacific Human Micobiome Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Micobiome Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Micobiome Market Size and Volume Forecast by Application
12.4.1. Treatment
12.4.2. Diagnosis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Micobiome Market Size and Volume Forecast by Type
12.7.1. Gastrointestinal Tract Human Micobiome
12.7.2. Urogenital Tract Human Micobiome
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Micobiome Demand Share, 2019-2026
13. Middle East & Africa Human Micobiome Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Micobiome Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Micobiome Market Size and Volume Forecast by Application
13.4.1. Treatment
13.4.2. Diagnosis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Micobiome Market Size and Volume Forecast by Type
13.7.1. Gastrointestinal Tract Human Micobiome
13.7.2. Urogenital Tract Human Micobiome
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Micobiome Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Micobiome Market: Market Share Analysis
14.2. Human Micobiome Distributors and Customers
14.3. Human Micobiome Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Vedanta
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Seres Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Second Genome
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Rebiotix
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ActoGeniX
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Enterome BioScience
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AvidBiotics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. 4D Pharma Research Ltd
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Enterologics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Metabogen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Metabiomics
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Ritter Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Osel
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Symberix
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Miomics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Symbiotix Biotherapies
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. MicroBiome Therapeutics LLC
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18.
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
